"Nevirapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
| Descriptor ID |
D019829
|
| MeSH Number(s) |
D03.383.725.506
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nevirapine".
Below are MeSH descriptors whose meaning is more specific than "Nevirapine".
This graph shows the total number of publications written about "Nevirapine" by people in this website by year, and whether "Nevirapine" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 2 | 1 | 3 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 3 | 2 | 5 |
| 2003 | 4 | 1 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 3 | 5 |
| 2006 | 3 | 3 | 6 |
| 2007 | 5 | 4 | 9 |
| 2008 | 4 | 5 | 9 |
| 2009 | 5 | 1 | 6 |
| 2010 | 4 | 4 | 8 |
| 2011 | 8 | 5 | 13 |
| 2012 | 7 | 4 | 11 |
| 2013 | 4 | 4 | 8 |
| 2014 | 8 | 4 | 12 |
| 2015 | 4 | 1 | 5 |
| 2016 | 1 | 2 | 3 |
| 2017 | 6 | 1 | 7 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 5 | 6 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 3 | 4 |
| 2022 | 2 | 3 | 5 |
| 2023 | 0 | 3 | 3 |
Below are the most recent publications written about "Nevirapine" by people in Profiles.
-
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024 Jan; 11(1):e20-e30.
-
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2023 04 15; 92(5):393-398.
-
Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies. J Int AIDS Soc. 2023 02; 26(2):e26032.
-
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clin Pharmacol Ther. 2023 03; 113(3):660-669.
-
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. AIDS. 2023 03 01; 37(3):413-421.
-
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis. J Int AIDS Soc. 2022 09; 25(9):e26001.
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
-
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Pediatr Infect Dis J. 2022 11 01; 41(11):885-890.
-
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. Clin Infect Dis. 2022 06 10; 74(11):2001-2009.
-
HIV Encephalopathy in ART-Naïve, Hospitalized Infants in Mozambique. J Trop Pediatr. 2021 12 08; 67(6).